XBiotech (XBIT) Operating Expenses (2014 - 2026)

XBiotech has reported Operating Expenses for 13 years, with the latest figure at $6.1 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 3.0% year-over-year to $6.1 million in Q2 2026; TTM through Jun 2026 was $48.3 million, a 32.15% increase from a year earlier, with the FY2025 full-year figure at $55.7 million, up 31.11% from the prior year.
• Operating Expenses was $6.1 million for Q2 2026 at XBiotech, down from $29.8 million in the prior quarter.
• The five-year high for Operating Expenses was $29.8 million in Q4 2025, with the low at $6.0 million in Q3 2025.
• Average Operating Expenses over 5 years is $10.6 million, with a median of $8.5 million recorded in 2023.
• The largest YoY upside for Operating Expenses was 240.13% in 2025 against a maximum downside of 57.66% in 2025.
• Over 5 years, Operating Expenses stood at $8.4 million in 2022, then increased by 1.67% to $8.6 million in 2023, then advanced by 1.87% to $8.7 million in 2024, then jumped by 240.13% to $29.8 million in 2025, then slumped by 79.34% to $6.1 million in 2026.
• The last three Operating Expenses figures came in at $6.1 million (Q2 2026), $29.8 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.